Suppr超能文献

糖皮质激素暴露与特定疾病美国患者队列中的骨折风险。

Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions.

机构信息

Amgen Inc., Thousand Oaks, CA, USA.

Wade Outcomes Research and Consulting, Salt Lake City, UT, USA.

出版信息

J Bone Miner Res. 2018 Oct;33(10):1881-1888. doi: 10.1002/jbmr.3523. Epub 2018 Aug 22.

Abstract

The purpose of this work was to evaluate systemic glucocorticoid exposure and fracture among patients with newly-diagnosed inflammatory and immune-modulated conditions. Using administrative data, inception cohorts of rheumatoid arthritis (RA), asthma/chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), multiple sclerosis (MS), lupus, and sarcoidosis patients age 18 to 64 years with benefits coverage ≥12 months before diagnosis (January 1, 2005 to December 31, 2012) were followed to clinical fracture, cancer diagnosis, or December 31, 2012. Glucocorticoid users were new to therapy. Fracture incidence rates (IRs) per 1000 person-years were stratified by prednisone equivalent doses. Cox's proportional hazards models assessed risk by daily and cumulative dose, and by time since discontinuation, adjusted for baseline characteristics. Most patients (72% of 403,337) had glucocorticoid exposure; 52% were under age 50. IR (95% confidence interval [CI]) of any osteoporotic fracture was elevated at doses <5 mg/day (IR 9.33; 95% CI, 7.29 to 11.77) versus 0 mg/day (IR 4.87 (95% CI, 4.72 to 5.02). Fracture rates were elevated at doses <5 mg/day in patients <50 years and those ≥50 years. In both age groups, fracture risk increased with increasing cumulative exposure, being approximately 2.5-fold higher at cumulative dose ≥5400 mg compared to <675 mg. At ≥5400 mg, IR values were 5.69 (95% CI, 4.32 to 7.35) in patients <50 years and 17.10 (95% CI, 14.97 to 19.46) in older patients. Fracture risk decreased significantly within months following glucocorticoid discontinuation. In patients with a variety of inflammatory conditions, fracture risk increased at doses as low as <5 mg/day. Risk increased with increasing cumulative exposure and decreased soon following glucocorticoid discontinuation. Trends were similar between patients older and younger than 50 years. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.

摘要

这项研究的目的是评估新诊断的炎症和免疫调节性疾病患者的全身糖皮质激素暴露与骨折之间的关系。使用行政数据,我们对年龄在 18 至 64 岁之间、在诊断前有≥12 个月福利覆盖期(2005 年 1 月 1 日至 2012 年 12 月 31 日)的类风湿关节炎(RA)、哮喘/慢性阻塞性肺疾病(COPD)、炎症性肠病(IBD)、多发性硬化症(MS)、狼疮和结节病患者的起始队列进行了随访,直到发生临床骨折、癌症诊断或 2012 年 12 月 31 日。糖皮质激素使用者是新开始治疗的。按泼尼松等效剂量对每 1000 人年的骨折发生率(IR)进行分层。Cox 比例风险模型根据每日和累积剂量以及停药后时间评估风险,调整了基线特征。大多数患者(403337 例中的 72%)有糖皮质激素暴露史;52%的患者年龄小于 50 岁。与 0mg/天(IR,4.87(95%置信区间,4.72 至 5.02)相比,任何骨质疏松性骨折的 IR(95%置信区间,7.29 至 11.77)在剂量<5mg/天时升高。在年龄<50 岁和年龄≥50 岁的患者中,剂量<5mg/天时骨折发生率均升高。在这两个年龄组中,随着累积暴露量的增加,骨折风险逐渐增加,累积剂量≥5400mg 与<675mg 相比,骨折风险约增加 2.5 倍。在累积剂量≥5400mg 时,年龄<50 岁的患者的 IR 值为 5.69(95%置信区间,4.32 至 7.35),年龄≥50 岁的患者为 17.10(95%置信区间,14.97 至 19.46)。在糖皮质激素停药后几个月内,骨折风险显著降低。在患有各种炎症性疾病的患者中,剂量低至<5mg/天时骨折风险增加。风险随累积暴露量的增加而增加,并在糖皮质激素停药后不久迅速下降。在年龄大于或小于 50 岁的患者中,趋势相似。© 2018 作者。由 Wiley Periodicals, Inc. 出版的《骨与矿物研究杂志》

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验